A multinational randomized, controlled, clinical trial of etoricoxib inthetreatment of rheumatoid arthritis [ISRCTN25142273]

BMC Family Practice

Volumn 3, Issue , 2002, Pages 1-10

  Collantes, Eduardo ^a   Curtis, Sean P ^b   Lee, Ka Wing ^c   Casas, Noemi ^d   McCarthy, Timothy ^e   Melian, Agustin ^b   Zhao, Peng L ^b   Rodgers, Diana B ^b   McCormick, Calogera L ^b   Lee, Michael ^b   Lines, Christopher R ^b   Gertz, Barry J ^b  

^a HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

^b MERCK RESEARCH LABORATORIES   (United States)

^c PAMELA YOUDE NETHERSOLE EASTERN HOSPITAL   (Hong Kong)

^d Laboratory of Pathology   (Colombia)

^e Manitoba Clinic   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ETORICOXIB; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PYRIDINE DERIVATIVE; SULFONE;

ABDOMINAL PAIN; ANGINA PECTORIS; ARTHRALGIA; ARTHROPATHY; ARTICLE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORNEA DYSTROPHY; DISEASE ACTIVITY; DOUBLE BLIND PROCEDURE; DRUG TOLERABILITY; DUODENUM ULCER; DYSPEPSIA; FEMALE; FEMUR FRACTURE; GASTROINTESTINAL REFLUX; HEADACHE; HEART ATRIUM FIBRILLATION; HEARTBURN; HUMAN; HYPERTENSION; INTERVERTEBRAL DISK HERNIA; LEG EDEMA; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; PAIN ASSESSMENT; PNEUMOTHORAX; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; RETINA DETACHMENT; RHEUMATOID ARTHRITIS; THROMBOPHLEBITIS; THYROID CANCER; TREATMENT FAILURE; TREATMENT OUTCOME; TREATMENT WITHDRAWAL; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; VOMITING; ARTHRITIS, RHEUMATOID; CHEMICALLY INDUCED; DRUG COMBINATION; MIDDLE AGED; PAIN MEASUREMENT;

ARTHRITIS, RHEUMATOID; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; DUODENAL ULCER; FEMALE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; NAPROXEN; PAIN MEASUREMENT; PYRIDINES; SULFONES;

EID: 34248674068     PISSN: 14712296     EISSN: None     Source Type: Journal    
DOI: 10.1186/1471-2296-3-10     Document Type: Article

References (19)

1. American College of Rheumatology Ad Hoc Committee on clinical guidelines: Guidelines for monitoring drug therapy in rheumatoid arthritis. Arthritis Rheum. 1996, 39:723-731
2. American College of Rheumatology Ad Hoc Committee on clinical guidelines: Guidelines for the management of rheumatoid arthritis. Arthritis Rheum. 1996, 39:713-722
3. Wolfe MM, Lichtenstein DR, Singh G: Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. N Engl J Med. 1999, 340:1888-1899
4. Fries JF, Williams CA, Bloch DA, Michel BA: Nonsteroidal anti-inflammatory drug-associated gastropathy: incidence and risk factor models. Am J Med. 1991, 91:213-222
5. van Riel PLCM, Wijnands MJH, van de Putte LBA: Evaluation and management of active inflammatory disease. In: Rheumatology. (Edited by: Klippel JH, Dieppe PA, Arnett FC) London: Mosby 1998, 14.1-14.2
6. Bombardier C, Laine L, Reicin A, et al: Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. New Engl J Med 2000, 343:1520-1528
7. Schnitzer TJ, Truitt K, Fleischmann R, et al: The safety profile, tolerability, and effective dose range of rofecoxib in the treatment of rheumatoid arthritis. Clinical Therapeutics 1999, 21:1688-1702
8. Emery P, Zeidler H, Kvien KT, et al: Celecoxib versus diclofenac in long-term management of rheumatoid arthritis: randomized double-blind comparison. Lancet 1999, 354:2106-2111
9. Matsumoto A, Melian A, Mandel DR, et al: A randomized, controlled, clinical trial of etoricoxib in the treatment of rheumatoid arthritis J Rheumatology 2002, in press
10. Felson DT, Anderson JJ, Boers M, et al: American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum. 1995, 38:727-735
11. Malmstrom K, Shahane A, Fricke JR, Ehrich E: MK -0663-an investigational COX-2 inhibitor: the effect in acute pain using the dental-impaction model. Arthritis Rheum. 2000, 43:S299 [Abstract]
12. Gottesdiener K, Schnitzer T, Fisher C, et al: MK-663, a specific COX-2 inhibitor for treatment of osteoarthritis (OA) of the knee. Arthritis Rheum. 1999, 42:S144 [Abstract]
13. Gottesdiener K, Schnitzer T, Fisher C, et al: Treatment with MK-663, a specific COX-2 inhibitor, resulted in clinical improvement in osteoarthritis (OA) of the knee that was sustained over three months. Ann Rheum Dis 2000, 59:133 [Abstract]
14. Brater DC, Harris C, Redfern JS, Gertz BJ: Renal effects of COX-2-selective inhibitors. Am J Nephrol. 2001, 21:1-15
15. Murray MD, Brater DC: Renal toxicity of the nonsteroidal anti-inflammatory drugs. Annu Rev Pharmacol Toxicol. 1993, 32:435-465
16. Langman MJ, Jensen DM, Watson DJ, et al: Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs. JAMA 1999, 282:1929-1933
17. Catella-Lawson F, Crofford LJ: Cyclooxygenase inhibition and thrombogenicity. Am J Med. 2001, 110:28S-32S
18. Mukherjee D, Nissen SE, Topol EJ: Risk of cardiovascular events associated with selective cox-2 inhibitors. JAMA 2001, 286:954-959
19. Curtis SP, Maldonado-Cocco J, Lozada B, et al: Characterization of the clinically effective dose range of MK-0663, a COX-2 selective inhibitor, in the treatment of rheumatoid arthritis. Arthritis Rheum 2000, 43:S226 [Abstract]